Decades of research have had an incredible impact on breast cancer. Today, many forms of the disease can be treated successfully when detected early. Once a tumor spreads, however, the likelihood of survival begins to plummet.  That troubling reality is starting to change thanks to former Damon Runyon Fellow David E. Lebwohl, MD, and a recent Phase III clinical trial in which survival time was doubled for its participants.

> Read the whole post: “New Therapy Dramatically Improves Breast Cancer Survival”